In a meta-analysis conducted by Giugliano et al. [79] (eight studies, n=60080), GLP-1 receptor agonists reduced MACE (14%), cardiovascular death (13%), nonfatal stroke (16%), HHF (10%), and all-cause mortality (12%). This evidence concerns the gene GLP1R and stroke disorder.